| dc.contributor.author | Crutchley, Rustin D. | |
| dc.contributor.author | Keuler, Nicole | |
| dc.date.accessioned | 2023-06-05T09:04:02Z | |
| dc.date.available | 2023-06-05T09:04:02Z | |
| dc.date.issued | 2022 | |
| dc.identifier.citation | Crutchley, R. D., & Keuler, N. (2022). Sub-analysis of cyp-guides data: Assessing the prevalence and impact of drug-gene interactions in an ethnically diverse cohort of depressed individuals. Frontiers in Pharmacology, 13, 884213. 10.3389/fphar.2022.884213 | en_US |
| dc.identifier.issn | 1663-9812 | |
| dc.identifier.uri | https://doi.org/10.3389/fphar.2022.884213 | |
| dc.identifier.uri | http://hdl.handle.net/10566/9007 | |
| dc.description.abstract | Minority groups are underrepresented in pharmacogenomics (PGx)
research. Recent sub-analysis of CYP-GUIDES showed reduced length of stay (LOS)
in depressed patients with CYP2D6 sub-functional status. Our primary objective was to
determine whether PGx guided (G) versus standard treatment (S) influenced LOS among
different race/ethnic groups. Secondary objectives included prevalence of drug-gene
interactions (DGIs) and readmission rates (RAR). Retrospective sub-analysis of CYP-GUIDES data comprising CYP2D6
phenotypes was reclassified using standardized CYP2D6 genotype to phenotype
recommendations from the Clinical Pharmacogenetics Implementation Consortium
(CPIC) and Dutch Pharmacogenetics Working Group (DPWG). | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Frontiers Media | en_US |
| dc.subject | Pharmaceutic | en_US |
| dc.subject | Pharmacology | en_US |
| dc.subject | Ethnicity | en_US |
| dc.subject | Race | en_US |
| dc.subject | Depression | en_US |
| dc.title | Sub-analysis of cyp-guides data: Assessing the prevalence and impact of drug-gene interactions in an ethnically diverse cohort of depressed individuals | en_US |
| dc.type | Article | en_US |
